No-Go'ing Back: Co-opting RVB-2 to Control HIV-1 Gene Expression and Immune Response.
Production of infectious HIV-1 particles requires viral envelope (Env) glycoprotein incorporation. Although, the precise mechanism remains elusive, interaction between Env and the matrix (MA) domain of Gag plays a central role. Work by Mu and colleagues demonstrates how the Env-MA interaction regulates gag mRNA stability and Gag expression levels.
HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada.
Valerie
V
Le Sage
HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada; Department of Medicine, McGill University, Montréal, Québec, H3A 0G4, Canada.
Alessandro
A
Cinti
HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada; Department of Medicine, McGill University, Montréal, Québec, H3A 0G4, Canada; Department of Microbiology and Immunology, McGill University, Montréal, Québec, H3A 0G4, Canada. Electronic address: andrew.mouland@mcgill.ca.
Andrew J
AJ
Mouland
D002352:Carrier Proteins / Q000378:metabolism*; D004265:DNA Helicases / Q000378:metabolism*; D015967:Gene Expression Regulation, Viral; D015497:HIV-1 / Q000502:physiology*; D054884:Host-Pathogen Interactions; D006801:Humans; D054299:env Gene Products, Human Immunodeficiency Virus / Q000096:biosynthesis*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000096:biosynthesis*
D002352:Carrier Proteins; D054299:env Gene Products, Human Immunodeficiency Virus; D054301:gag Gene Products, Human Immunodeficiency Virus; D004265:DNA Helicases
Envelope (Env); Gag; Genomic RNA; HIV-1; No-go mRNA decay; RuvB-like 2 (RVB-2)